Besifloxacin Ophthalmic Suspension 0.6% in the Treatment of Bacterial Keratitis: A Retrospective Safety Surveillance Study

Schechter, Barry A.; Parekh, J. G.; Trattler, William

doi:10.1089/jop.2014.0039

Cited by 10 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown to be effective in a rabbit model of keratitis and reduced MRSA colony-forming units more effectively than gatifloxacin or moxifloxacin [48]. A retrospective study showed that besifloxacin treatment of human cases of bacterial keratitis yielded no serious adverse effects and had low incidences of corneal scarring or neovascularization similar to that seen with moxifloxacin treatment [50]. …”

Section: Resistant Strainsmentioning

confidence: 99%

Challenges of corneal infections

Hazlett

Suvas

McClellan

et al. 2016

Expert Review of Ophthalmology

View full text Add to dashboard Cite

Introduction Ocular infections remain an important cause of blindness worldwide and represent a challenging public health concern. In this regard, microbial keratitis due to fungal, bacterial, or viral infection can result in significant vision loss secondary to corneal scarring or surface irregularity. Left untreated corneal perforation and endophthalmitis can result, leading to loss of the eye. Rigorously studied animal models of disease pathogenesis have provided novel information that suggests new modes of treatment that may be efficacious clinically and emerging clinical data is supportive of some of these discoveries. Areas covered This review focuses on advances in our understanding of disease pathogenesis in animal models and clinical studies and how these relate to improved clinical treatment. We also discuss a novel approach to treatment of microbial keratitis due to infection with these bacterial pathogens using PACK-CXL and recommend increased basic and clinical studies to address and refine the efficacy of this procedure. Expert commentary Because resistance to antibiotics has developed over time to these bacterial pathogens, caution must be exercised in treatment. Attractive novel modes of treatment that hold new promise for further investigation include lipid based therapy, as well as use of small molecules that bind deleterious specific host responsive molecules and use of microRNA based therapies.

show abstract

Section: Resistant Strainsmentioning

confidence: 99%

Challenges of corneal infections

Hazlett

Suvas

McClellan

et al. 2016

Expert Review of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Following months of treatment with a regimen of multiple topical antibiotic agents, including besifloxacin, the ulcer resolved leaving a minimal corneal scar. A retrospective chart review by Schechter et al of more than 200 patients with bacterial keratitis found similar treatment outcomes ( P ≥ 0.208) between besifloxacin-treated patients ( n = 142) and those treated with moxifloxacin ( n = 85), although the results were confounded by inclusion of other topical antibacterials in the therapeutic regimen for some patients [ 69 ]. The frequency and duration of besifloxacin and moxifloxacin use varied but did not differ, with a median duration of 15 days for both treatment groups and a final dosing frequency of 4 or more times daily for the majority of patients.…”

Section: Resultsmentioning

confidence: 99%

Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections

Mah

Sanfilippo²

2016

Ophthalmol Ther

View full text Add to dashboard Cite

This comprehensive review summarizes the mechanism of action, pharmacokinetics, efficacy, and safety of besifloxacin ophthalmic suspension, 0.6% and examines its role in the treatment of ocular surface bacterial infections. Besifloxacin possesses balanced activity against bacterial topoisomerase II (also called DNA gyrase) and topoisomerase IV. It has shown a low potential to select for bacterial resistance in vitro and demonstrated strong in vitro activity against many Gram-positive, Gram-negative, and anaerobic organisms, including methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis (MRSA and MRSE, respectively). Ocular pharmacokinetic studies have shown that besifloxacin achieves high, sustained concentrations in the tear fluid and conjunctiva following topical administration, with negligible systemic exposure. Large randomized, controlled clinical trials have established the efficacy and safety of besifloxacin administered three times daily for 5 days for treatment of acute bacterial conjunctivitis in both adults and children, with high rates of clinical resolution (up to more than 70% by day 5) and bacterial eradication (more than 90% by day 5), and a low incidence of adverse events. Additionally, besifloxacin applied twice daily for 3 days demonstrated greater efficacy than vehicle in treating bacterial conjunctivitis. Case reports, a large retrospective chart review, and animal studies have provided supporting evidence for the efficacy of besifloxacin in the management of acute bacterial keratitis. There is some evidence to suggest that besifloxacin may provide an advantage over other current-generation fluoroquinolones in antimicrobial prophylaxis for ocular surgery. Besifloxacin is an appropriate option for treatment of bacterial conjunctivitis, and its use in the treatment of bacterial keratitis and lid disorders, as well as for surgical prophylaxis, appears promising and warrants further evaluation.

show abstract

“…8 A large, retrospective, case surveillance study showed that besifloxacin was as safe as moxifloxacin in the treatment of bacterial keratitis, with similar low incidences of corneal scarring and neovascularisation, and similar rates of physician-assesed bacterial eradication. 9 Along with the efficacy demonstrated by besifloxacin against S.aureus, P.aerugenosa, and serratia species in patients with bacterial conjunctivitis. These results suggest a potential role for besifloxacin in the treatment of bacterial keratitis.…”

Section: Discussionmentioning

confidence: 96%